140 results on '"Gopalan, Anuradha"'
Search Results
2. Histopathologic and Molecular Characterization of IDH-Mutant Prostatic Adenocarcinoma
3. Differential NEUROD1, ASCL1, and POU2F3 Expression Defines Molecular Subsets of Bladder Small Cell/Neuroendocrine Carcinoma With Prognostic Implications
4. L1 Cell Adhesion Molecule (L1CAM) Expression and Molecular Alterations Distinguish Low-Grade Oncocytic Tumor From Eosinophilic Chromophobe Renal Cell Carcinoma
5. Treatment-related Neuroendocrine Prostate Carcinoma—Diagnostic and Molecular Correlates
6. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy
7. Papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome
8. TERT Copy Number Alterations, Promoter Mutations and Rearrangements in Adrenocortical Carcinomas
9. Novel Androgen Receptor Splice Variant 7 in Gynecologic Tumors.
10. Genomic characterization of metastatic patterns from prospective clinical sequencing of 25,000 patients
11. Author Correction: FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
12. FOXA1 repression drives lineage plasticity and immune heterogeneity in bladder cancers with squamous differentiation
13. Safety and immunological effects of ablative radiotherapy followed by pembrolizumab in patients with advanced adrenocortical carcinoma.
14. Novel Androgen Receptor Splice Variant 7 in Gynecologic Tumors
15. Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer
16. Impact of Zone of Origin in Anterior Dominant Prostate Cancer: Long-Term Biochemical Recurrence-Free Survival in an Anatomically Well-Characterized Cohort
17. Single Cell Analysis of Treatment-Resistant Prostate Cancer: Implications of Cell State Changes for Cell Surface Antigen Targeted Therapies
18. The neuroendocrine transition in prostate cancer is dynamic and dependent on ASCL1
19. BET inhibitors as a therapeutic intervention in gastrointestinal gene signature-positive castration-resistant prostate cancer
20. Clinical and Genomic Characterization of Bladder Carcinomas With Glandular Phenotype
21. Single-cell analysis of treatment-resistant prostate cancer: Implications of cell state changes for cell surface antigen-targeted therapies.
22. Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer
23. Ganglioneuroblastoma intermixed: Clinicopathological implications of diagnosis at presentation and genomic correlations
24. ERG-driven prostate cancer emerges from basal-luminal hybrid cells
25. ETV4 mediates dosage-dependent prostate tumor initiation and cooperates with p53 loss to generate prostate cancer
26. Abstract NG10: Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
27. Data from Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
28. Supplementary Table S1 from Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
29. Supplementary Figure S3 from Androgen Receptor Signaling Regulates DNA Repair in Prostate Cancers
30. Data from Characterization of KRAS Rearrangements in Metastatic Prostate Cancer
31. Supplementary Methods and Data (posted 7/5/2011) from Characterization of KRAS Rearrangements in Metastatic Prostate Cancer
32. Supplementary Methods, Figures, Tables, and References from Characterization of KRAS Rearrangements in Metastatic Prostate Cancer
33. Supplementary Table 1 from Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2
34. Data from Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2
35. Supplementary Figure Legend from Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2
36. Supplementary Figures from Oncogenic ERG Represses PI3K Signaling through Downregulation of IRS2
37. Data from TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy
38. Supplementary Tables 1-2 from TMPRSS2-ERG Gene Fusion Is Not Associated with Outcome in Patients Treated by Prostatectomy
39. Effect of Janus kinase (JAK) signaling inhibition on lineage plasticity and drug sensitivity in castrate resistant prostate cancer.
40. Gene-based Confirmatory Germline Testing Following Tumor-only Sequencing of Prostate Cancer
41. Abstract B026: Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
42. Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
43. Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists
44. Neuroendocrine differentiation in the setting of prostatic carcinoma: contemporary assessment of a consecutive series
45. Abstract 1728: Single cell RNA-seq analysis reveals a role of pro-inflammatory tumor-associated macrophages in driving prostate cancer progression
46. Abstract 2200: Multilineage plasticity in prostate cancer through expansion of stem-like luminal epithelial cells with elevated inflammatory signaling
47. Chromatin profiles classify castration-resistant prostate cancers suggesting therapeutic targets
48. Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies
49. sj-docx-1-ijs-10.1177_10668969221116629 - Supplemental material for Reporting Trends, Practices, and Resource Utilization in Neuroendocrine Tumors of the Prostate Gland: A Survey among Thirty-Nine Genitourinary Pathologists
50. Long-term Outcomes of Local and Metastatic Small Cell Carcinoma of the Urinary Bladder and Genomic Analysis of Patients Treated With Neoadjuvant Chemotherapy.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.